Biosimilar erythropoietin in anemia treatment (BEAT) - Efficacy and safety of a 1:1 dose conversion from EPREX<sup>®</sup>to EPIAO<sup>®</sup>in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study

6

punsarn.item.page.citation

Miao B., Isachkina A.N., Shutov E.V., Selyutin A.A., Kvitkova L.V., Shilo V.Y., Vetchinnikova O.N., Alexandrov I.V., Perlin D.V., Zuev A.V., Davydkin I.L., Mironova T.P., Solovyova O.M., Tutin A.P., Omelchenko A.M., Vareesangthip K., Khadikova N.G., Li M., Li X. Biosimilar erythropoietin in anemia treatment (BEAT) - Efficacy and safety of a 1:1 dose conversion from EPREX<sup>®</sup>to EPIAO<sup>®</sup>in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study. Medicine (United States) Vol.101 No.47 (2022) , E31426. doi:10.1097/MD.0000000000031426 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85368

item.page.availability

Collections